N.B. Bui
About
N.B. Bui is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology.
According to data from OpenAlex, N.B. Bui has authored 23 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Gastroenterology. Recurrent topics in N.B. Bui's work include Sarcoma Diagnosis and Treatment (17 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Vascular Tumors and Angiosarcomas (4 papers). N.B. Bui is often cited by papers focused on Sarcoma Diagnosis and Treatment (17 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Vascular Tumors and Angiosarcomas (4 papers). N.B. Bui collaborates with scholars based in France, United States and Luxembourg. N.B. Bui's co-authors include F. Bonichon, G Contesso, M Trojani, Jacques Rouëssé, C Lagarde, J.‐F. Goussot, A. de Mascarel, Marc David, Jean‐Michel Coindre and J.M. Coindre and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
In The Last Decade
N.B. Bui
22 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N.B. Bui France | 11 | 1.5k | 984 | 573 | 544 | 372 | 23 | 1.8k | ||
| J.M. Coindre France | 11 | 1.4k 0.9× | 865 0.9× | 531 0.9× | 423 0.8× | 247 0.7× | 31 | 1.7k | ||
| Marc David Canada | 17 | 1.5k 1.0× | 809 0.8× | 417 0.7× | 449 0.8× | 337 0.9× | 49 | 1.9k | ||
| Yasuo Beppu Japan | 29 | 1.5k 1.0× | 674 0.7× | 681 1.2× | 349 0.6× | 376 1.0× | 76 | 2.2k | ||
| M. Ouali France | 19 | 1.4k 1.0× | 957 1.0× | 350 0.6× | 454 0.8× | 291 0.8× | 46 | 1.8k | ||
| B. Bui France | 24 | 1.5k 1.0× | 826 0.8× | 580 1.0× | 372 0.7× | 451 1.2× | 63 | 2.0k | ||
| Thomas F. DeLaney United States | 14 | 1.8k 1.2× | 1.2k 1.2× | 660 1.2× | 429 0.8× | 492 1.3× | 22 | 2.0k | ||
| Binh Bui Nguyen France | 12 | 1.1k 0.7× | 658 0.7× | 275 0.5× | 410 0.8× | 208 0.6× | 49 | 1.3k | ||
| Angela Cioffi France | 22 | 1.5k 1.0× | 958 1.0× | 387 0.7× | 460 0.8× | 384 1.0× | 55 | 2.2k | ||
| Hirokazu Chuman Japan | 25 | 1.1k 0.7× | 460 0.5× | 542 0.9× | 273 0.5× | 530 1.4× | 73 | 1.6k | ||
| M O Vilain France | 15 | 1.9k 1.3× | 1.4k 1.5× | 618 1.1× | 757 1.4× | 255 0.7× | 34 | 2.4k |
Countries citing papers authored by N.B. Bui
Since
Specialization
Citations
This map shows the geographic impact of N.B. Bui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N.B. Bui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N.B. Bui more than expected).
Fields of papers citing papers by N.B. Bui
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by N.B. Bui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N.B. Bui. The network helps show where N.B. Bui may publish in the future.
Co-authorship network of co-authors of N.B. Bui
This figure shows the co-authorship network connecting the top 25 collaborators of N.B. Bui. A scholar is included among the top collaborators of N.B. Bui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N.B. Bui. N.B. Bui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Blay, Jean‐Yves, A. Le Cesne, N.B. Bui, et al.. (2011). Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial.. Journal of Clinical Oncology. 29(4_suppl). 85–85.
2.
Schöffski, Patrick, I. L. Ray-Coquard, Angela Cioffi, et al.. (2010). Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).. Journal of Clinical Oncology. 28(15_suppl). 10031–10031.
3.
Reichardt, Peter, Jean‐Yves Blay, Hans Gelderblom, et al.. (2010). Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.. Journal of Clinical Oncology. 28(15_suppl). 10017–10017.
4.
Blay, Jean‐Yves, N.B. Bui, Philippe A. Cassier, et al.. (2010). Correlation of the topography of KIT exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.. Journal of Clinical Oncology. 28(15_suppl). 10019–10019.
5.
Cesne, Axel Le, Isabelle Ray‐Coquard, N.B. Bui, et al.. (2010). Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.. Journal of Clinical Oncology. 28(15_suppl). 10033–10033.
6.
Gronchi, Alessandro, Emanuela Palmerini, George D. Demetri, et al.. (2009). 9400 A phase II clinical trial of neoadjuvant trabectedin in patients with non metastatic advanced myxoid/round cell liposarcoma (MRCL). European Journal of Cancer Supplements. 7(2). 590–590.
7.
Gronchi, Alessandro, Axel Le Cesne, N.B. Bui, et al.. (2009). A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). Journal of Clinical Oncology. 27(15_suppl). 10525–10525.
8.
Culine, Stéphane, Pierre Kerbrat, A. Kramar, et al.. (2007). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Annals of Oncology. 18(5). 917–924.
9.
Germain, Pierre, N.B. Bui, T. Traissac, et al.. (2000). Syndrome de Schnitzler: une cause rare d'urticaire systémique. La Revue de Médecine Interne. 21(3). 285–289.
10.
Kantor, G., et al.. (1998). Chimiothérapie des sarcomes des tissus mous de l'adulte. Cancer/Radiothérapie. 2(6). 747–751.
11.
Coindre, J.M., Philippe Terrier, N.B. Bui, et al.. (1996). Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.. Journal of Clinical Oncology. 14(3). 869–877.
12.
Fizazi, Karim, Nadine Dohollou, M. Spielmann, et al.. (1995). 1200 Adults with Ewing's sarcoma: A retrospective study of 146 cases. European Journal of Cancer. 31. S250–S250.
13.
Chevallier, B, N.B. Bui, F. Bonichon, et al.. (1993). Efficacy of lenograstim on hematological tolerance to maid chemotherapy in sarcoma patients and impact on dose intensity. European Journal of Cancer. 29. S186–S186.
14.
Verweij, Jaco J., M. Clavel, G. Catimel, et al.. (1993). Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult. European Journal of Cancer. 29. S183–S183.
15.
Ravaud, Alain, N.B. Bui, Coindre Jm, et al.. (1992). Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. British Journal of Cancer. 66(5). 961–969.
16.
Robert, Jacques & N.B. Bui. (1992). Original article: Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Annals of Oncology. 3(8). 651–656.
17.
Robert, Jacques, N.B. Bui, & Patricia Vrignaud. (1987). Pharmacokinetics of doxorubicin in sarcoma patients. European Journal of Clinical Pharmacology. 31(6). 695–699.
18.
Bui, N.B., et al.. (1984). Liposarcoma: Patterns of Tumor Differentiation Following Induction Chemotherapy. Oncology. 41(3). 170–173.
19.
Trojani, M, G Contesso, Jean‐Michel Coindre, et al.. (1984). Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. International Journal of Cancer. 33(1). 37–42.
20.
Chauvergne, J, N.B. Bui, P Cappelaere, et al.. (1982). [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].. PubMed. 58(46). 2697–701.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J.M. Coindre Breakdown of academic impact, for papers by Marc David Breakdown of academic impact, for papers by Yasuo Beppu Breakdown of academic impact, for papers by M. Ouali Breakdown of academic impact, for papers by B. Bui Breakdown of academic impact, for papers by Thomas F. DeLaney Breakdown of academic impact, for papers by Binh Bui Nguyen Breakdown of academic impact, for papers by Angela Cioffi Breakdown of academic impact, for papers by Hirokazu Chuman Breakdown of academic impact, for papers by M O Vilain